Safety and Efficacy Study in Patients With Major Depressive Disorder
NCT00896363
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
99
Enrollment
INDUSTRY
Sponsor class
Conditions
Depressive Disorder
Interventions
DRUG:
GSK163090 1 mg
DRUG:
GSK163090 Placebo
DRUG:
GSK163090 3 mg
Sponsor
GlaxoSmithKline